Clinical Trial Update: A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and activity study of SBT6050 in combination with other HER2-directed therapies for HER2-positive cancers; the trial status is terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Expressing Non-small Cell Lung Cancer
• Gastric Cancer

Drugs mentioned

• SBT6050

Snippet

Sponsor: Silverback Therapeutics | Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-08-18